NCT03162224 - Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions

Head and Neck CancerHuman Papilloma Virus

Interventions

DRUG

MEDI0457

MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.

DEVICE

CELLECTRA®5P device

MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.

DRUG

Durvalumab

Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.

Trial Locations (14)

10461

Research Site, The Bronx

19104

Research Site, Philadelphia

21201

Research Site, Baltimore

21287

Research Site, Baltimore

27157

Research Site, Winston-Salem

30308

Research Site, Atlanta

32806

Research Site, Orlando

43210

Research Site, Columbus

46202

Research Site, Indianapolis

48201

Research Site, Detroit

55414

Research Site, Minneapolis

63110

Research Site, St Louis

94115

Research Site, San Francisco

07960

Research Site, Morristown